Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

No respite for Indian indices
Mon, 8 Jul 01:30 pm

Backed by persistent selling activity across index heavyweights, Indian equity markets continued to trade weak during the post noon trading session. Most of the sectoral indices are trading in the negative territory. Stocks from the PSU and realty sectors are witnessing maximum selling pressure. However IT, healthcare and FMCG stocks are in favour today.

BSE-Sensex is down by 192 points and NSE-Nifty is trading down by 63 points. While BSE Mid Cap is trading down by 0.2%, BSE Small Cap index is trading down by 0.4%. The rupee is trading at 60.94 to the US dollar.

Majority of the PSU banking stocks are trading in the red with UCO Bank and Corporation Bank being the leading losers. As per a leading financial daily, State Bank of India (SBI), may launch a new home loan product. This would help various home loan borrowers to avail higher credit with a lower rate of interest. Reportedly, the proposal is submitted and the final nod is awaited from an internal policy making body, CCPPC (Credit Pricing and Processing Committee). The said committee will finalize the same in the next few weeks. Currently, the bank is offering loans in two slabs viz., upto Rs 30 lakhs and above Rs 30 lakhs. As per the new proposal, these slabs will be raised to Rs 40-50 lakhs. Both the Reserve Bank of India (RBI) and the government have been insisting that banks pass on the rate cut benefits to borrowers. Moreover, the regulators want banks to facilitate the housing sector especially those who fall under the low cost bracket. SBI was trading down by 1.3%.

Indian pharma stocks are trading mixed. While Panacea Biotech and Torrent Pharma are trading firm, Strides Arcolab and Elder Pharma are at the receiving end. As per a financial daily, Wockhardt Ltd, has received an import alert from the UK (United Kingdom) drug regulator MHRA (Medicines and Healthcare products Regulatory Agency)on its Waluj facility located at Aurangabad. This is the same facility where some time back the USFDA (United States Food and Drug Authority) had issued import alert. As per the company, this alert accounts for approximately Rs 1 bn of the sales of the company. However, the company is looking for alternative site transfers immediately and thus expects very negligible impact due to this ban. Wockhardt was trading up by 0.6%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "No respite for Indian indices". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.